Kidswell Bio Corporation (TYO:4584)

Market Cap	7.34B +30.8%
Revenue (ttm)	6.59B +29.7%
Net Income	-413.00M
EPS	-8.46
Shares Out	49.62M
PE Ratio	n/a
Forward PE	7.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	719,100
Open	150.00
Previous Close	150.00
Day's Range	144.00 - 151.00
52-Week Range	143.00 - 417.00
Beta	1.12
Analysts	n/a
Price Target	n/a
Earnings Date	May 14, 2026

About Kidswell Bio

Kidswell Bio Corporation develops pharmaceutical products for the treatment of pediatric, pediatric, intractable, and Asia-endemic diseases in Japan. Its pipeline products include GBS-001 and GBS-010 for oncology; GBS-007 for ophthalmic disease; and GBS-011 for renal disease. The company pipeline products also include GCT-103 that is indicated for pediatric cerebral palsy; GCT-102 for congenital entero-neuropathy; SQ-104 for osteonecrosis of the femoral head; modified thymidine kinase for glioblastoma; and Gene X for spinal cord injury. The com...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 37
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4584

Financial Performance

In fiscal year 2026, Kidswell Bio's revenue was 6.59 billion, an increase of 29.65% compared to the previous year's 5.08 billion. Losses were -413.00 million, 1866.7% more than in 2025.